Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von Maxim Group 

Panbela Therapeutics Inc. diskutieren

Panbela Therapeutics Inc.

WKN: A3EHA0 / Symbol: PBLA / Name: Panbela Therapeutics / Aktie / Micro Cap /

90,36 €
-

Panbela Therapeutics, Inc. (NASDAQ: PBLA) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating.
Ratings data for PBLA provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 14,44
Veränderung
Endet am 24.07.24

Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for PBLA provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,00 %
Kursziel 14,61
Veränderung
Endet am 11.08.24

Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for PBLA provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 22,90
Veränderung
Endet am 18.12.24

Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $25.00 price target on the stock.
Ratings data for PBLA provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 23,26
Veränderung
Endet am 05.02.25

Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its price target lowered by analysts at Roth Mkm from $500.00 to $25.00. They now have a "buy" rating on the stock.
Ratings data for PBLA provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 23,10
Veränderung
Endet am 27.03.25

Panbela Therapeutics, Inc. (NASDAQ: PBLA) had its "buy" rating re-affirmed by analysts at Roth Mkm. They now have a $25.00 price target on the stock.
Ratings data for PBLA provided by MarketBeat